Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Effectiveness and Safety of MRZF111 in the Treatment of Décolleté Wrinkles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female between ≥18 and ≤65 years old.~* Décolleté wrinkles with a rating of moderate to severe (grade 2 to 3) on the MAS Décolleté Wrinkles-At Rest as determined by the blinded live rater and confirmed by the treating investigator afterwards.~Exclusion Criteria:~* Any previous treatment with fat injections, poly L-lactic acid or permanent dermal fillers (e.g., silicone, polymethyl methacrylate) in the décolleté.~* Any previous surgery, including plastic surgery, or surgical permanent implant in the décolleté or in the breasts that could interfere with effectiveness and safety.~* Any previous thread lifting in the décolleté.~* Previous treatment with collagen fillers, calcium hydroxylapatite (CaHa), and/or long-lasting hyaluronic acid (HA) fillers (e.g., Belotero® Intense/Volume, Juvéderm® Volift/Volbella) in the décolleté within the past 24 months before baseline.~* Previous treatment with other HA fillers in the décolleté within the past 12 months before baseline.~* Previous treatment with botulinum toxin, ablative or fractional laser, microdermabrasion, microneedling, chemical peels and/or non-invasive skin tightening (e.g., ultrasound, radiofrequency, intense pulsed light treatment) in the décolleté within the past 6 months before baseline.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 3 MRZF111 injection cycles (Type: EXPERIMENTAL): Enrolled subjects will receive 3 injection cycles in total at time points Day 1, Week 8, and Week 16.
- 2 MRZF111 injection cycles (Type: EXPERIMENTAL): Enrolled subjects will receive 2 injection cycles in total at time points Day 1, and Week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).